The effect of Brahmi vati and Sarpagandha Ghana vati in management of essential hypertension - A randomized, double blind, controlled clinical study.
Essential hypertension (EHTN) is emerging as one of the most prevalent disorder with higher rate of complications, morbidity and mortality. Brahmi vati, an Ayurvedic medicine is explored for its efficacy in the management of EHTN. 68 patients of age group 20-60 years, of either sex meeting the JNC 7 criteria of EHTN were randomly divided into two groups, group A and group B. Group A and group B received capsule Brahmi vati 500 mg and capsule Sarpagandha Ghana vati 500 mg respectively twice a day for 30 days. Assessments were done through various variables like systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), lipid profiles, Hamilton anxiety rating scale, 2 weeks sleep diary, serum creatinine, hemoglobin, total leukocyte count and erythrocyte sedimentation rate. Follow up visit was on every 15th day. Study showed that both Brahmi vati and Sarpagandha Ghanavati produced significant improvement in most of the variables and were comparable. Significant improvements were seen in various variables like SBP, DBP, MAP, Hamilton anxiety rating scale, subjective sleep profiles and total cholesterol. However Brahmi vati showed significant increase in weight and Body Mass Index (BMI). SarpagandhaGhanavati produced reduction in total cholesterol and LDL. Both groups showed good safety profile evaluated through serum creatinine assessment. Clinical efficacy of Sarpagandha Ghana vati and Brahmi vati on EHTN showed that both were effective, safe and comparable. Both were comprehensively effective in management of EHTN.